Kintara Therapeutics announced a record date of October 17, 2024, for issuing Contingent Value Rights (CVRs) to stockholders in connection with its merger with TuHURA Biosciences, expected to close on October 18, 2024, entitling stockholders to 53,897,125 shares of common stock, subject to a reverse stock split of 1-for-35.